Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INLIGHT: WVE-007 in Adults With Overweight or Obesity
NCT06842186Phase 2Recruiting
- Sponsor
- Wave Life Sciences
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of WVE-007 in obesity (7 cohorts), sponsored by Wave Life Sciences. Primary endpoint: Proportion of participants with treatment emergent adverse events. Started Jan 2025; status: recruiting.
02
Drugs
WVE-007
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06842186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06842186.